Biocon Limited, an innovation-led global biopharmaceutical company, announced the signing of a partnership agreement with Juno Pharmaceuticals, a specialty pharmaceutical company in Canada, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.
TORONTO--(BUSINESS WIRE)--Today, Juno Pharmaceuticals Canada (“Juno”), a leader in the commercialization of specialty pharmaceuticals, announced the acquisition of Omega Laboratories (“Omega”), one of Canada’s largest domestic specialty injectable pharmaceutical manufacturers. The new combined company is now one of the largest specialty generic injectable businesses in Canada with domestic manufacturing capabilities.
Juno Pharmaceuticals receives approval to import Eptifibatide as Canadian hospitals continue to grapple with shortages of critical medicines
TORONTO--(BUSINESS WIRE)--Juno Pharmaceuticals Canada (“Juno”), a Canadian specialty pharmaceutical company, announced that it has received approval from Health Canada to import Amoxicillin powder for oral suspension (“Amoxicillin”) pursuant to Health Canada’s exceptional importation and sale guidelines. This approval will help relieve the current nationwide shortage of a critical antibiotic product and most importantly, allow it to reach pediatric and geriatric patients alike. Through this initiative with both its vendor partners and importation approval from Health Canada, Juno has procured close to 100,000 bottles. Delivery of the first order is underway with the remaining orders expected throughout January. The product will be distributed to hospitals, pharmacies and retail wholesalers in every province and territory.
TORONTO--(BUSINESS WIRE)--Juno Pharmaceuticals Corp (“Juno”), a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth.
A Seattle-based biotech led by veterans of Genentech Inc., UCSF and Juno Therapeutics disclosed that it had raised $700 million to advance its cell engineering work and hire more people.
China’s oncology-focused biotech hub has raised already millions in venture funding and lured powerful global biopharma partners to address the high rates of cancer in the country. In yet another example, the joint venture between Juno and to WuXi’s AppTec has raised a sizable $100 million in a fresh round of funding.
Gilead’s bid to overturn a jury verdict that ordered it to pay Bristol Myers Squibb about $752 million for CAR-T patents owned by its subsidiary Juno Therapeutics has ended in vain.
The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.
As Kite Pharma won approval for and launched its first CAR-T med Yescarta, the company was infringing a Juno Therapeutics patent, a lawsuit claims.